Trial · NCT01209598

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

NCT01209598, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2017-11-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma. Trials, record NCT01209598. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01209598

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
NCT number: NCT01209598
Status: Completed
Phases: Phase 2
Enrollment: 90 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Sarcoma, Liposarcoma
Interventions: Palbociclib 200mg, Palbociclib 125mg
First posted: 2010-09-27
Last updated: 2017-11-06
Results first posted: 2017-11-06

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival at 12 Weeks	12 weeks	PFS, defined as RECIST 1.1 (CR + PR + SD) when treated with Palbociclib
Secondary	Best Response	2 years	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival at 12 Weeks	12 weeks		percentage of particpants	MEDIAN
SECONDARY	Best Response	2 years		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression Free Survival at 12 Weeks	Palbociclib 200mg		66	95% Confidence Interval 51 to 100	percentage of particpants
Progression Free Survival at 12 Weeks	Palbociclib 125mg		57.2	95% Confidence Interval 42.4 to 68.8	percentage of particpants
Best Response	Palbociclib 200mg	Partial Response	1		Participants
Best Response	Palbociclib 125mg	Partial Response	0		Participants
Best Response	Palbociclib 200mg	Complete Response	0		Participants
Best Response	Palbociclib 125mg	Complete Response	1		Participants
Best Response	Palbociclib 200mg	Stable Disease	5		Participants
Best Response	Palbociclib 125mg	Stable Disease	8		Participants
Best Response	Palbociclib 200mg	Progression of Disease	23		Participants
Best Response	Palbociclib 125mg	Progression of Disease	50		Participants

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Palbociclib 200mg	30
Overall Study	STARTED	Palbociclib 125mg	60
Overall Study	COMPLETED	Palbociclib 200mg	29
Overall Study	COMPLETED	Palbociclib 125mg	60
Overall Study	NOT COMPLETED	Palbociclib 200mg	1
Overall Study	NOT COMPLETED	Palbociclib 125mg	0

Source ClinicalTrials.gov

Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anorexia	Metabolism and nutrition disorders	Palbociclib 200mg	2	30
other	Anorexia	Metabolism and nutrition disorders	Palbociclib 125mg	0	60
other	Dizziness	Nervous system disorders	Palbociclib 200mg	2	30
other	Dizziness	Nervous system disorders	Palbociclib 125mg	0	60
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Palbociclib 200mg	2	30
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Palbociclib 125mg	0	60
other	Edema limbs	General disorders	Palbociclib 200mg	2	30
other	Edema limbs	General disorders	Palbociclib 125mg	0	60
other	Epistaxis	Respiratory, thoracic and mediastinal disorders	Palbociclib 200mg	2	30
other	Epistaxis	Respiratory, thoracic and mediastinal disorders	Palbociclib 125mg	0	60

1 to 10 of 66Source ClinicalTrials.gov

See all 66 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Palbociclib 200mg
Total, all-cause mortality	Palbociclib 125mg
Total, other adverse events	Palbociclib 200mg	30	30
Total, other adverse events	Palbociclib 125mg	60	60
Total, serious adverse events	Palbociclib 200mg	24	30
Total, serious adverse events	Palbociclib 125mg	55	60

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
23569312	DERIVED	PubMed
27124835	DERIVED	PubMed
32641862	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Palbociclib 200mg vs Palbociclib 125mg: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01209598

GET https://conductscience.org/api/trials/v1/NCT01209598/events?page=2

API reference For AI assistants